Volver a Agenda
[V4-S4] It’s Time to Think About Compliance to Deliver Value Added Medical Information - Current and Ideal Situation of Medical Iformation Provision
Session Chair(s)
D. Stuart Sowder, JD, PHARMD, MBA
Vice President, Compliance Lead, Asia, Pacific, Africa, Middle East, Pfizer Holdings, United States
Following the daily changing scientific and ethical approach, data building that collected our wisdom will be the basis of application for approval. How should we provide the approved data to health care professionals and contribute to the improvement of medical quality? The advertisement activity surveillance monitor system began and entered the second year. It seems that the time has come when we must consider for our actions and ethical standards together with our stakeholders instead of considering the compliance by a single organization. In this session, we are going to discuss the current or future direction in Japan following global trend regarding medical information provision with compliance experts from each pharmaceutical association (JPMA, PhRMA, EFPIA), academia and regulatory authority.
Speaker(s)
It’s Time to Think About Compliance to Deliver Value Added Medical Information -Current and Ideal Situation of Medical Information Provision-
Corporate Officer, Country Medical Director and Head of Medical Japan, Pfizer Japan Inc., Japan
Initiatives Toward Appropriate Advertisement Activities in JPMA
Managing Director, Japan Pharmaceutical Manufacturers Association (JPMA), Japan
Problems of Drug Promotion Activities Emerging from Report from Advertisement Surveillance Monitoring
Professor, Faculty of Pharmaceutical Sciences, Teikyo Heisei University, Japan
Guidelines on Pharmaceutical Product Communications
Legal Advisor, Compliance and Narcotics Division, Ministry of Health, Labour and Welfare (MHLW), Japan
Kunio Kawajiri
Healthcare Compliance Group, Ethics & Compliance Department, Astellas Pharma Inc., Japan
Kana Matsumura
Legal Counsel, Legal, Sanofi K.K., Japan
¿Tiene una cuenta?